动脉瘤性蛛网膜下腔出血后低剂量静脉肝素输注与延迟性神经功能缺损及脑梗死风险降低相关
该回顾性队列比较分析纳入556例动脉瘤性蛛网膜下腔出血患者,比较低剂量静脉肝素输注(12 U/kg/h)与标准皮下肝素预防深静脉血栓的院内结局。
要点
- 多因素回归显示低剂量静脉肝素与延迟性神经功能缺损(OR 0.53)和脑梗死(OR 0.40)风险降低相关。
- 两组出血并发症、肝素诱导性血小板减少症和深静脉血栓发生率无差异。
核心结论
- 低剂量静脉肝素输注可能改善动脉瘤性蛛网膜下腔出血患者的结局,但需前瞻性研究进一步评估。
研究设计与样本
- 单中心10年期间556例连续动脉瘤性蛛网膜下腔出血病例的回顾性队列比较分析,动脉瘤经夹闭或栓塞处理。
- 低剂量静脉肝素组233例接受12 U/kg/h静脉肝素输注,皮下肝素组323例接受5000 U每日3次皮下肝素预防深静脉血栓。
- 采用多因素logistic回归和倾向评分逆概率治疗加权(IPTW)比较两组影像学和结局数据。
主要发现
- 多因素logistic回归显示低剂量静脉肝素组延迟性神经功能缺损风险较低(OR 0.53,95%CI 0.33-0.85)。
- 多因素logistic回归显示低剂量静脉肝素组脑梗死风险较低(OR 0.40,95%CI 0.23-0.71)。
- IPTW分析显示类似结果。
- 两组出血并发症、肝素诱导性血小板减少症和深静脉血栓发生率无差异。
临床怎么用
- 低剂量静脉肝素输注可能作为动脉瘤性蛛网膜下腔出血后预防延迟性神经功能缺损和脑梗死的策略,但证据来自回顾性队列,需前瞻性研究验证。
局限性
- 回顾性队列比较分析,存在选择偏倚等固有局限。
- 单中心研究,结果外推需谨慎。
- 作者指出需前瞻性研究进一步评估低剂量静脉肝素输注的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients who survive aneurysmal subarachnoid hemorrhage (aSAH) are at risk for delayed neurological deficits (DND) and cerebral infarction. In this exploratory cohort comparison analysis, we compared in-hospital outcomes of aSAH patients administered a low-dose intravenous heparin (LDIVH) infusion (12 U/kg/h) vs those administered standard subcutaneous heparin (SQH) prophylaxis for deep vein thrombosis (DVT; 5000 U, 3 × daily). OBJECTIVE: To assess the safety and efficacy of LDIVH in aSAH patients. METHODS: We retrospectively analyzed 556 consecutive cases of aSAH patients whose aneurysm was secured by clipping or coiling at a single institution over a 10-yr period, including 233 administered the LDIVH protocol and 323 administered the SQH protocol. Radiological and outcome data were compared between the 2 cohorts using multivariable logistic regression and propensity score-based inverse probability of treatment weighting (IPTW). RESULTS: The unadjusted rate of cerebral infarction in the LDIVH cohort was half that in SQH cohort (9 vs 18%; P = .004). Multivariable logistic regression showed that patients in the LDIVH cohort were significantly less likely than those in the SQH cohort to have DND (odds ratio (OR) 0.53 [95% CI: 0.33, 0.85]) or cerebral infarction (OR 0.40 [95% CI: 0.23, 0.71]). Analysis following IPTW showed similar results. Rates of hemorrhagic complications, heparin-induced thrombocytopenia and DVT were not different between cohorts. CONCLUSION: This cohort comparison analysis suggests that LDIVH infusion may favorably influence the outcome of patients after aSAH. Prospective studies are required to further assess the benefit of LDIVH infusion in patients with aSAH.
引用
- Kole MJ, Wessell AP, Ugiliweneza B, et al. Low-Dose Intravenous Heparin Infusion After Aneurysmal Subarachnoid Hemorrhage is Associated With Decreased Risk of Delayed Neurological Deficit and Cerebral Infarction. Neurosurgery. 2021. PMID: 33269390. doi:10.1093/neuros/nyaa473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。